Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

March 24, 2023

Study Completion Date

July 31, 2024

Conditions
Diabetic Neuropathy, Painful
Interventions
BIOLOGICAL

Engensis

Intramuscular injections

OTHER

Placebo

Intramuscular injections

Trial Locations (16)

10314

Richmond Behavioral Associates, Staten Island

20110

Manassas Clinical Research Center, Manassas

23219

Dominion Medical Associates, Richmond

23510

Eastern Virginia Medical School, Norfolk

33756

Innovative Research of West Florida, Inc., Clearwater

57702

Health Concepts, Rapid City

62269

Gateway Clinical Trials, LLC, O'Fallon

62704

Foot & Ankle Center of Illinois, Springfield

63005

Clinical Research Professionals, Chesterfield

72205

Clinical Trials - Little Rock, Little Rock

75165

ClinPoint Trials LLC, Waxahachie

77030

Nerve and Muscle Center of Texas, Houston

78501

Futuro Clinical Trials, LLC, McAllen

85053

Arizona Research Center, Phoenix

90048

California Medical Clinic for Headache, Los Angeles

95821

Clinical Trials Research - Sacramento, Sacramento

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY

NCT04469270 - Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter